From Medscape Oncology

Medscape Medical News from the:

2011 European Multidisciplinary Cancer Congress (EMCC)

September 23 - 27, 2011; Stockholm, Sweden

This coverage is not sanctioned by, nor a part of the European Society for Medical Oncology, the European Cancer Organisation, or the European Society for Radiotherapy and Oncology.

Meeting Highlights at a Glance

Top News Stories From the 2011 EMCC
Research presented included practice-changing results from a large number of late-breaking phase 3 clinical trials, including SECRAB, BOLERO-2, and a study of the investigational radiopharmaceutical radium-223 chloride in prostate cancer.

Oncology Insights: The Wrap-up

EMCC Wrap-up: mTOR and More
Drs. David Kerr and Jean-Charles Soria discuss the highlights of the EMCC meeting, focusing on practice-changing trials.

Conference News

Medscape Oncology©  WebMD, LLC

Medscape Oncology Insights

Wanted: Better Tumor Marksmanship
Jean-Charles Soria, MD

T-DM1: Why So Much Interest?
Gunter von Minckwitz, MD,
Fabrice André, MD, PhD

Lung Cancer: A Shooting Gallery of Targets
Giorgio V. Scagliotti, MD, PhD;
Thierry Le Chevalier, MD

Prostate Cancer: A Treatment Renaissance
Johann S. de Bono, PhD, MSc

Colorectal Cancer: New Data, New Insights
Eric Van Cutsem, MD, PhD

Ovarian Cancer: New Treatment Options
Stanley B. Kaye, MD

Pre-Meeting Expert Commentary

Preview of Practice-Changing Data From ECCO/ESMO
David J. Kerr, MD